Co techniques. Conclusions These data represent evidence that many patient-specific neoantigens may be identified by means of functional proof of T cell response from peripheral blood with out epitope prediction. By profiling organic and CPI-enhanced immunity to neoantigens, a broad catalog of T cell targets may be identified for improvement of immunotherapies that engage T cells against cancer to enhance outcomes for individuals for whom current therapies are insufficient.P356 Genome-scale neoantigen screening utilizing ATLASTM prioritizes candidates for immunotherapy in a non-small cell lung cancer patient Lila Ghamsari1, Emilio Flano1, Judy Jacques1, Biao Liu1, Jonathan Havel2, Vladimir Makarov2, Taha Merghoub3, Jedd D Wolchok4, Matthew D Hellmann4, Timothy A Chan2, Jessica B Flechtner1 1 Genocea Biosciences, Cambridge, MA, USA; 2Memorial Sloan Kettering Cancer Center, New York, NY, USA; 3Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 4 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA Correspondence: Jessica B Flechtner ([email protected]) Journal for ImmunoTherapy of Cancer 2016, four(Suppl 1):PP357 Targeting tumor vasculature with a DNA vaccine against NPY Y1 receptor Antagonist review endosialin (TEM1 or CD248) Pierini Stefano, Andrea Facciabene, John Facciponte, Stefano Ugel, Francesco De Sanctis, George Coukos University of Pennsylvania, Philadelphia, PA, USA Correspondence: Pierini Stefano ([email protected]) Journal for ImmunoTherapy of Cancer 2016, four(Suppl 1):P357 Background Tumor endothelial marker 1 (TEM1; also called endosialin or CD248) is often a protein located on tumor vasculature and in tumor stroma. Methods Here, we tested no matter if TEM1 has prospective as a PPARβ/δ Activator site therapeutic target for cancer immunotherapy by immunizing immunocompetent mice with Tem1 cDNA fused for the minimal domain of the C fragment of tetanus toxoid (referred to herein as Tem1-TT vaccine). ResultsJournal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):Web page 190 ofTem1-TT vaccination elicited CD8+ and/or CD4+ T cell responses against immunodominant TEM1 protein sequences. Prophylactic immunization of animals with Tem1-TT prevented or delayed tumor formation in quite a few murine tumor models. Therapeutic vaccination of tumor-bearing mice reduced tumor vascularity, improved infiltration of CD3+ T cells into the tumor, and controlled progression of established tumors. Tem1-TT vaccination also elicited CD8+ cytotoxic T cell responses against murine tumorspecific antigens. Helpful Tem1-TT vaccination didn’t impact angiogenesis-dependent physiological processes, which includes wound healing and reproduction. Conclusions Depending on these data as well as the widespread expression of TEM1 on the vasculature of different tumor kinds, we conclude that targeting TEM1 has therapeutic prospective in cancer immunotherapy.the percentage of mice protected against live CT 26 challenge was markedly increased for mice vaccinated with cells treated with HfO2 nanoparticles exposed to 6Gy versus 6Gy alone (66 vs 33 respectively). Conclusions HfO2 nanoparticles exposed to irradiation enhanced cancer cells destruction and ICD in comparison to irradiation alone, suggesting a powerful possible for transforming tumor into an effective in situ vaccine. They might contribute to transform “cold” tumor into “hot” tumor and effectively be combined with most of the immunotherapeutic agents across oncology.P358 Hafnium oxide nanoparticle, a radiation enhancer for in.